CPRX - Catalyst Pharmaceuticals Inc
IEX Last Trade
20.24
0.260 1.285%
Share volume: 714,458
Last Updated: Fri 30 Aug 2024 09:59:52 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$19.98
0.26
1.30%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-09 | 2023-03-15 | 2023-05-10 | 2023-08-09 | 2023-11-08 | 2024-02-28 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 267.309 M | 333.114 M | 375.630 M | 407.227 M | 443.896 M | 413.211 M | 470.114 M | 646.676 M | |
| Current Assets | 242.558 M | 276.310 M | 320.797 M | 198.911 M | 240.968 M | 192.017 M | 219.329 M | 404.602 M | |
| Inventories | 7.850 M | 7.132 M | 6.805 M | 10.328 M | 10.751 M | 9.035 M | 15.644 M | 19.953 M | |
| Other Current Assets | 4.333 M | 3.776 M | 5.158 M | 6.934 M | 8.634 M | 13.962 M | 12.535 M | 13.745 M | |
| Short Term Investments | 4.333 M | 3.776 M | 5.158 M | 6.934 M | 8.634 M | 13.962 M | 12.535 M | 13.745 M | |
| Total Receivables | 9.587 M | 9.337 M | 10.439 M | 33.402 M | 42.796 M | 48.049 M | 53.514 M | 60.493 M | |
| Current Cash | 220.788 M | 256.065 M | 298.395 M | 148.247 M | 178.787 M | 120.971 M | 137.636 M | 310.411 M | |
| Total Non-current Assets | 24.751 M | 56.804 M | 54.833 M | 208.316 M | 202.928 M | 221.194 M | 250.785 M | 242.074 M | |
| Property Plant Equipment | 917.000 K | 882.000 K | 847.000 K | 1.285 M | 1.203 M | 1.186 M | 1.195 M | 1.308 M | |
| Other Assets | 9.000 K | 9.000 K | 9.000 K | 0.000 | 0.000 | 12.897 M | 16.489 M | 15.345 M | |
| Intangible Assets | 0.000 | 33.051 M | 32.471 M | 184.083 M | 175.595 M | 167.108 M | 194.049 M | 184.705 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 267.309 M | 333.114 M | 375.630 M | 407.227 M | 443.896 M | 413.211 M | 470.114 M | 646.676 M | |
| Total liabilities | 26.217 M | 63.073 M | 75.209 M | 73.566 M | 68.602 M | 64.663 M | 82.233 M | 85.264 M | |
| Total current liabilities | 22.488 M | 44.681 M | 57.588 M | 56.709 M | 52.503 M | 57.806 M | 76.063 M | 79.566 M | |
| Accounts Payable | 2.315 M | 2.529 M | 3.975 M | 3.391 M | 4.421 M | 4.598 M | 14.795 M | 10.261 M | |
| Other liabilities | 0.000 | 14.749 M | 14.064 M | 13.389 M | 12.723 M | 3.575 M | 2.982 M | 2.607 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 14.749 M | 14.064 M | 13.389 M | 12.723 M | 3.575 M | 2.982 M | 2.607 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 241.092 M | 270.041 M | 300.421 M | 333.661 M | 375.294 M | 348.548 M | 387.881 M | 561.412 M | |
| Common stock | 102.796 M | 103.319 M | 104.602 M | 105.561 M | 106.259 M | 106.568 M | 106.731 M | 116.806 M | |
| Retained earnings | 1.643 M | 24.391 M | 49.862 M | 79.430 M | 117.192 M | 86.428 M | 121.272 M | 144.547 M |